Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine.

Chromatin architecture is frequently altered in cancers, including one of the most prevalent cancers, hepatocellular carcinoma (HCC). Emerging evidence suggests that liquid-liquid phase separation ...

This study aims to develop a safer and more effective CAR T cell therapy for hepatocellular carcinoma (HCC). While recent clinical trials have shown promise, IL15-GPC3-CAR T cells demonstrated a 33% ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

The trial compared the combo against the investigator’s choice of tyrosine kinase inhibitor monotherapy in the unresectable or advanced hepatocellular carcinoma patient group. Credit: ...

Abstract: Early screening to improve the survival rate of hepatocellular carcinoma (HCC) patients remains a critical clinical challenge. However, current methods for early cancer detection still lack ...

The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This regulatory decision is ...